Navigation Links
Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
Date:6/30/2008

rmanently modify the DNA sequence encoding CCR5, a co-receptor that enables HIV to enter and infect cells of the immune system. Individuals carrying a naturally occurring mutation of their CCR5 gene, a variant known as CCR5-delta32, have been shown to be resistant to HIV infection.

"The data described in this paper are an important demonstration of the potential therapeutic properties of our product," commented Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "We have demonstrated that a single treatment with our CCR5-specific ZFNs generates a population of HIV-resistant human T-cells similar to the situation in individuals carrying the natural CCR5-delta32 mutation. ZFN-modification of these cells is permanent and makes them resistant to HIV. The modified cells preferentially survive and expand in an animal after HIV infection, providing a reservoir of healthy and uninfectable immune cells. Furthermore, we observed that animals given the ZFN-modified cells had increased numbers of CD4 cells and substantially lower levels of HIV in their blood compared to animals given non-modified cells demonstrating statistically significant protection from the virus. In an HIV-infected patient, such modified cells could be available as a protected reservoir within the immune system to fight both opportunistic infections and HIV itself."

Several major pharmaceutical companies have initiated programs to develop small molecule or monoclonal antibody approaches to block the binding of HIV to CCR5. However, a small molecule or antibody approach requires the constant presence of a sufficiently high concentration of these drugs or antibody to block therapeutically relevant numbers of the CCR5 protein, which is present in thousands of copies on the surface of each T-cell and other tissues in the body. One such drug has been approved by the US Food and Drug Administration with a "black box" warning, the strongest for prescriptio
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
2. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
3. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
6. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
7. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
8. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
9. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
10. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
11. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  HealthLoop® released an app ... HealthKit in iOS 8 and allows people to share ... app harnesses native iOS technologies to enhance the HealthLoop ... robust connection with their doctors between visits. ... the data they collect is exciting," says HealthLoop founder ...
(Date:9/30/2014)... Sept. 30, 2014  Proteomics is a focus ... new report from Kalorama Information.  The healthcare market research ... in proteomics in the past two years.  The ... between private proteomic companies and academic institutions, to ... proteomics innovator companies.  Kalorama observed the industry in ...
(Date:9/30/2014)... SAN DIEGO , 30. September ... Logo - http://photos.prnewswire.com/prnh/20130430/LA01948LOGO ... ein Medizintechnikunternehmen, das ein minimal-invasives 3D-Herzkammer-Bildgebungs- ... der Ursachen entwickelt, die zu komplexen ... aufrechterhalten, hat den Abschluss einer zusätzlichen ...
Breaking Medicine Technology:HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3
... DEERFIELD, Ill., and LONDON, Aug. 16 Baxter,International ... Baxter,s European,subsidiary in the United Kingdom has entered ... Health that contains an option to purchase,pandemic influenza ... (WHO),declares a pandemic. Baxter will manufacture its ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) a ... proprietary product candidates for the treatment,of cancer ... U.S. Food and,Drug Administration (FDA) has granted ... which is currently being investigated in a,pivotal ...
Cached Medicine Technology:Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health 2Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health 3ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3
(Date:9/30/2014)... University of Maryland-led research team has been awarded ... Institutes of Health (NIH) to develop new imaging ... our understanding of how large networks of neurons ... This knowledge will help researchers identify the precise ... behavior, like decision-making and speaking, and alterations in ...
(Date:9/30/2014)... Elevate , the latest product from ... and out of the gym by providing natural ingredients that ... of Shane Michaels, prompting an investigative review. , “When ... most people simply just don’t have the ability to perform ... work, getting the motivation to finish a project, or even ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Hospice ... its annual “In Celebration” gala, honoring three outstanding ... mission of striving to provide extraordinary and dignified ... facing a serious or life-limiting illness. , The ... in Rye, NY and recognized William (Bill) J. ...
(Date:9/30/2014)... Dr. Karl R.O.S. Johnson, DC, has ... of care that is dramatically improving the health and ... Neurology & Nutrition—applies a proprietary, multi-dimensional approach that goes ... sources of inflammation, neurology of the joint and neurology ... the brain to the spine, to the legs, knees ...
(Date:9/30/2014)... 2014) Levothyroxine is considered the gold standard therapy ... review of therapies for the condition including combining ... assessment, say a team of investigators.,1Their analysis, published as ... , finds insufficient consistent data exist to recommend a ... sold under various trade names, such as Synthroid ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2
... that the U.S. Food and Drug Administration has approved ... prostate cancer patients, marks the beginning of an era ... the standard therapeutic arsenal against cancer, say Dana-Farber Cancer ... effectiveness in patients. The study the results ...
... ... Illness (NAMI), NAMIWalks help raise funds for local programs. , ... (PRWEB) -- May is Mental Health Month. This weekend, Saturday ... NAMIWalks to raise public awareness about facts concerning mental illness and the ...
... from all drugs used to prevent organ rejection, researchers ... type of drug treatment used to prevent organ rejection ... new study finds. , Kidney transplant patients are at ... use of immunosuppressive drugs to prevent organ rejection. In ...
... ... gastroenterologists from around the world to launch the first international “World IBD Day” dedicated ... conference (May 2 -5) in New Orleans. , ... New York, New York (Vocus) April 29, 2010 -- ...
... of ill people triggered greater response than pictures of gun-wielding ... a sick person may give your immune system a boost, ... sets of slides on two different days. The first set ... either a slideshow that showed photos of people with pox, ...
... This release is available in French . ... in Immunology and Cancer (IRIC) of the Universit de Montral ... ribonucleic acid (RNA) engineering laboratory in Canada. Led by Franois ... of Gerardo Ferbeyre, biochemistry researcher with the Faculty of Medicine ...
Cached Medicine News:Health News:Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments 2Health News:Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments 3Health News:NAMIWalks Kicks-off “Mental Health Month”; Fun Events that Support Serious Work 2Health News:Cancer Risk After Kidney Transplant Unaffected by Type of Drug Treatment 2Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 2Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 3Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 4Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 5Health News:Cells programmed to cure and even prevent cancer 2
... Streptavidin magnetic beads are designed ... biotinylated molecules such as DNA, ... cell lysates or hybridization reactions. ... dispersed, it can also be ...
... Streptavidin magnetic beads are ... covalently coupled to a ... substrates can be useful ... experiments including mRNA isolation ...
... For the detection P.falciparum ... and pan specific pLDH, for differentiation ... other malarial species viz P.vivax ... P. malariae and for the ...
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
Medicine Products: